anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD).
METHODS: Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression, the association between clinical measures and mortality was investigated. The impact of DMARDs was analysed by (1) Cox regression considering cumulative exposure (ie, treatment months divided by total months) and (2) time-varying Cox regression as main approach (treatment exposures at monthly level).
RESULTS: Out of 15 566 participants, 381 were identified as RA-ILD cases with 1258 person-years of observation and 2.6 years median length of follow-up. Ninety-seven patients (25.5%) died and 34 (35.1%) of these were not receiving DMARD therapy at the time of death. Higher inflammatory biomarkers but not swollen and tender joint count were significantly associated with mortality. Compared with tumour necrosis factor inhibitors (TNFi), non-TNFi biologic DMARDs (bDMARDs) exhibited adjusted HRs (aHRs) for mortality below 1, lacking statistical significance. This finding was stable in various sensitivity analyses. Joint aHR for non-TNFi biologics and JAKi versus TNFi was 0.56 (95% CI 0.33 to 0.97). Receiving no DMARD treatment was associated with a twofold higher mortality risk compared with receiving any DMARD treatment, aHR 2.03 (95% CI 1.23 to 3.35).
CONCLUSIONS: Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD. Non-TNFi bDMARDs may confer enhanced therapeutic benefits in patients with RA-ILD.
Obesity is a major risk factor for the development of life-threatening malignant ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD). Risks may be highest for patients with high levels of the proinflammatory cytokine interleukin (IL)-6. We used our guinea pig model of high-fat diet (HFD)-induced arrhythmias that exhibit a heightened proinflammatory-like pathology, which is also observed in human obesity arrhythmias, as well as immunofluorescence and confocal microscopy approaches to evaluate the pathological IL-6 trans-signaling function and explore the underlying mechanisms. Using blind-stick and electrocardiogram (ECG) techniques, we tested the hypothesis that heightened IL-6 trans-signaling would exhibit increased ventricular arrhythmia/SCD incidence and underlying arrhythmia substrates. Remarkably, compared to low-fat diet (LFD)-fed controls, HFD promoted phosphorylation of the IL-6 signal transducer and activator of transcription 4 (STAT4), leading to its activation and enhanced nuclear translocation of pSTAT4/STAT4 compared to LFD controls and pSTAT3/STAT3 nuclear expression. Overactivation of IL-6 trans-signaling in guinea pigs prolonged the QT interval, which resulted in greater susceptibility to arrhythmias/SCD with isoproterenol challenge, as also observed with the downstream Janus kinase (JAK) 2 activator. These findings may have potentially profound implications for more effective arrhythmia therapy in the vulnerable obese patient population.
The invention discloses medium-chain triglyceride (MCT) nano-emulsion and a preparation method thereof. The MCT nano-emulsion is prepared from the following components in parts by weight: 10-90 parts of MCT (1), 24-50 parts of glycerinum (2), 1-50 parts of egg yolk lecithin (3), 1-50 parts of Tween 80 (4) and 700-950 parts of purified water (5). The MCT is prepared into oral fatty nano-emulsion, so that the absorbing speed of fatty nutrients is increased. The egg yolk lecithin and the Tween 80 are mixed into an emulsifier, so that lecithin nutrient components are increased, and cholesterol metabolism is facilitated. Through nutrient components such as medium-chain fatty acid and the lecithin, the product plays a very good role in regulating metabolic disturbance of human body fat. Meanwhile, the MCT is prepared into the nano-emulsion, so that the uncomfortable symptoms of nausea, emesis, diarrhea or abdominal spastic pain and the like caused by orally taking of the MCT can be avoided.
PURPOSE:A safe cosmetic, obtained by blending capsules, containing a volatile oil and a resin soluble therein contained in a resin insoluble in the contained oil and resin as a capsule membrane and readily broken under pressure of fingers or sponges in application to the skin and having novel feeling of use. CONSTITUTION:A cosmetic obtained by blending capsules of compression disintegrable flexible resin containing a volatile oil, e.g. n-hexane, benzene, toluene, low-boiling isoparaffin, etc., and a resin soluble therein in a resin insoluble in the contained oil and resin, e.g. methacrylic acid, vinyl acetate, styrene, polyester, etc., as a shell (capsule membrane). The amounts of the volatile oil and resin soluble therein which are contained in the capsules of the compression disintegrable flexible resin is 10-95wt%, preferably 50-95wt% based on the total weight of the capsules. The cosmetic is capable of blending the volatile oil even with a solid foundation, pencil-type cosmetic, etc.
Hypertrophic cardiomyopathy (HCM) is characterized by thickening of the left ventricular wall, diastolic dysfunction, and fibrosis, and is associated with mutations in genes encoding sarcomere proteins. While in vitro studies have used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to study HCM, these models have not examined the multicellular interactions involved in fibrosis. Using engineered cardiac microtissues (CMTs) composed of HCM-causing MYH7-variant hiPSC-CMs and wild-type fibroblasts, we observed cell-cell cross-talk leading to increased collagen deposition, tissue stiffening, and decreased contractility dependent on fibroblast proliferation. hiPSC-CM conditioned media and single-nucleus RNA sequencing data suggested that fibroblast proliferation is mediated by paracrine signals from MYH7-variant cardiomyocytes. Furthermore, inhibiting epidermal growth factor receptor tyrosine kinase with erlotinib hydrochloride attenuated stromal activation. Last, HCM-causing MYBPC3-variant CMTs also demonstrated increased stromal activation and reduced contractility, but with distinct characteristics. Together, these findings establish a paracrine-mediated cross-talk potentially responsible for fibrotic changes observed in HCM.
Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
PURPOSE: An ultrasound imaging system and method for analysis usage the same are provided to measure productivity within a department which performs ultra-sound examinations. CONSTITUTION: The ultrasound imaging system includes a mobile main unit(10) which is transportable on a plurality of wheels(12). The main unit includes a housing(14), an operator panel(16) and a display monitor(18). The housing(14) has a plurality of ports by means of which a plurality of transducer probes(20) can be coupled to the signal processing subsystem located inside housing(14). Typically each probe is designed to meet the requirements of a specific application. The transducers fall into four general categories: phased array, linear, convex and specialty. Each transducer probe is coupled to a respective port of the ultrasound imaging system via a coaxial cable(22) and a transducer connector(24).
Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
PURPOSE: To explore study participants' experiences with chronic hematologic malignancies and their perspectives on symptom management based on patient-reported outcomes during follow-up care.
METHODS: This qualitative descriptive study used semi-structured telephone interviews conducted from May 2022 to February 2023. A purposeful sample was recruited, with participants invited consecutively. Participants were adults ≥18 years diagnosed with a chronic hematological malignancy and participating in a symptom management intervention. Reflexive thematic analysis, as described by Braun and Clarke, was used to perform an inductive analysis of the interview data.
RESULTS: A total of 19 telephone interviews were conducted with 17 participants. Participants had nuanced perspectives on managing life with a chronic and uncommon hematological malignancy reflected in the following themes: not allowing the disease to dominate, struggling to understand and manage the disease, navigating everyday life with the disease, and evaluating impact and tailoring of patient reported outcome-based symptom management.
CONCLUSION: This study emphasizes the ambiguity of living with a chronic hematological malignancy. Participants strive to prevent the disease from dominating their lives, despite their struggles to understand and manage the disease. The use of patient-reported outcomes in dialogue and targeted symptom management helped participants navigate daily life challenges. These findings underscore important considerations for enhancing follow-up care for patients with chronic hematological malignancies.
In this editorial, we discussed the apparent discrepancy between the findings described by Colapietro et al, in their case report and data found in the literature. Colapietro et al reported a case of hepatitis B virus (HBV)-related hepatic decompensation in a patient with chronic myeloid leukemia and a previously resolved HBV infection who was receiving Bruton's tyrosine kinase (BTK) inhibitor therapy. First of all, we recapitulated the main aspects of the immune system involved in the response to HBV infection in order to underline the role of the innate and adaptive response, focusing our attention on the protective role of anti-HBs. We then carefully analyzed literature data on the risk of HBV reactivation (HBVr) in patients with previous HBV infection who were treated with either tyrosine kinase inhibitors or BTK inhibitors for their hematologic malignancies. Based on literature data, we suggested that several factors may contribute to the different risks of HBVr: The type of hematologic malignancy; the type of therapy (BTK inhibitors, especially second-generation, seem to be at a higher risk of HBVr than those with tyrosine kinase inhibitors); previous exposure to an anti-CD20 as first-line therapy; and ethnicity and HBV genotype. Therefore, the warning regarding HBVr in the specific setting of patients with hematologic malignancies requires further investigation.
The BCG vaccine has been widely available for several decades. It is easy and cheap to produce, and when given to neonates or young children it is effective in preventing severe manifestations of disease such as meningeal tuberculosis and miliary tuberculosis. However, in terms of the capacity of the vaccine to protect adult humans it shows a wide range of efficacy, including zero levels of protection. Due to the general realization that BCG is losing its protective effect, particularly in terms of preventing adult-onset tuberculosis, a major effort has been made to try to develop new alternative vaccines. One such candidate, Mtb72F/AS02A, is a polyprotein derived from two known M. tuberculosis antigens adjuvanted with AS02A. Mtb72F/AS02A is a candidate TB vaccine under development for two indications: prevention of primary TB infection in young children in highly endemic areas and as an adjunct to treatment for TB in adolescents and adults.
Reactive oxygen species (ROS) scavenging of nanozymes toward acute kidney injury (AKI) is a current promising strategy, however, the glomerular filtration barrier (GFB) limits their application for treating kidney related diseases. Here, a neutrophil-mediated delivery system able to hijack neutrophil to transport nanozyme-loaded cRGD-liposomes to inflamed kidney for AKI treatment by cRGD targeting integrin αvβ1 is reported. The neutrophil-mediated nanozyme delivery system demonstrated great antioxidant and anti-apoptosis ability in HK-2 and NRK-52E cell lines. Moreover, in ischemia-reperfusion (I/R) induced AKI mice, a single dose of LM@cRGD-LPs 12 h post-ischemia significantly reduces renal function indicators, alleviates renal pathological changes, and inhibits apoptosis of renal tubular cells and the expression of renal tubular injured marker, thus remarkably reducing the damage of AKI. Mechanistically, the treatment of LM@cRGD-LPs markedly inhibits the process of Nrf2 to the nucleus and reduces the expression of the downstream HO-1, achieves a 99.51% increase in renal tissue Nrf2 levels, and an 86.31% decrease in HO-1 levels after LM@cRGD-LPs treatment. In short, the strategy of neutrophil-mediated nanozyme delivery system hold great promise as a potential therapy for AKI or other inflammatory diseases.
The present invention relates to a method for making Wutian liver caring liquid. Wutian liver caring liquid is used for treating alcoholic hepatitis, drug hepatitis and fatty livers and reverseing the change of hepatic fibrosis. The present invention aims to clear heat from the liver, eliminate dampness and remove toxin, stasis meridian and obstruction. The formula of the Wutian liver caring liquid comprises herba hyperici japonici, strngy stonecrop herb, Chinese magnoliavine fruit, patrinia, red sage root, haw, cassia occidentalis semen cassiae torae, oriental waterplantain rhizome, bupleurum root and raw liquorice root in the mixing proportion by weight of 6:6:4:4:3:3:3:2:2:1. After the medicine in the mixing proportion is filled in an extractor, 10 liters of water is filled in the extractor. When the medicine is decocted for 45 minutes at the temperature of 50 DEG C to 70 DEG C, medicine liquid can be extracted and packaged under the condition of guaranteeing not to lose effective ingredients of the medicine.
During the study participants will wear the transcranial photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
PROBLEM TO BE SOLVED: To obtain the subject preparation having moisturizing effect of excellent stability with time and esp. excellent in usability, by including specific acetylated hyaluronic acid and a gummy matter in specified proportions. SOLUTION: This preparation is obtained by formulating (A) 0.001-10 wt.% of an acetylated hyaluronic acid 2-4 in the number of substitution of acetyl groups per hyaluonic acid constitutive unit, with molecular weight of pref. 10,000-1000,000 in terms of hyaluronic acid, (B) 0.001-5 wt.% of a gummy matter (e.g. xanthan gum) so as to be (100:1) to (1:500) in the weight ratio A/B), and (C) as necessary, surfactant, oil, moisturizer, ultraviolet light absorber, alcohol, chelating agent, antiseptic, thickening agent, color, perfume, etc. The ingredient A is formed, for example, by dispersing powdery hyaluronic acid in acetic acid followed by reaction in the presence of trifluoroacetic acid as catalyst.
The method for the manufacture of a composition for the treatment of osteoarthritis in subjects involves the use of mesenchymal stem cells (MSC). These MSCs are derived from at least two healthy donors who are different from the subject to be treated. The MSCs are morphologically healthy and substantially free of senescent cells. They are also free of pathogens characteristic of the species and possess the main characteristics of MSCs. During propagation, the cumulative population doubling value (CPD value) of the MSCs is preferably in the range of 3 to 14. The level of kynurenine metabolite production of the MSCs is in the range of 30 to 50 ng/ml, and the level of THBS1 cytokine production of the MSCs is in the range of 50 to 80 ng/ml. The number of cells used is in the range of 105 to 5×107.
Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. Finally, the patients will be enrolled in a peri-implant maintenance therapy (PIMT) program every 3 months.
The post-operative ICU course for children receiving liver transplants and TPIAT (total pancreatectomy with islet cell autotransplantation) includes a number of different challenges, one of which includes pain. Pain is treated with both medications and approaches without medications (such as music and other distraction techniques). Opioids are one such effective pain medication which is universally used, however like all medications has risks of certain side effects (such as nausea, constipation, itching, and others). Modern research has searched for other medications and methods to treat pain in both children and adults. In this study, the investigators aim to apply one of these methods that has been shown to be effective in certain operative populations through a medicine called Magnesium-Sulfate, which may be a safe way to decrease the use of other pain medications (specifically opioids). Magnesium is already a physiologic electrolyte the body uses, which are consumed from certain foods. Used as an IV medication to reach higher levels of magnesium can work to decrease pain via its action on specific nerve receptors. Magnesium-Sulfate will be given at the beginning of transplant surgery for consented liver and TPIAT transplant patients, and continue an infusion for 48 hours into their ICU course. The investigators will monitor side effects and treat pain the same way otherwise the care team would without magnesium to determine whether there is any beneficial effect that can be applied to children in the future.
Patients with histories of repeated traumatization in childhood often display a wide array of symptoms described as complex traumatic stress disorder. This sequela involves a high degree of comorbid mental and somatic disturbances, and entails tremendous health care costs for society and suffering for the victims. Despite the prevalence and consequences of complex trauma, research on effective treatments is extremely limited. Expert clinicians suggest that initial treatment for these patients should focus on stabilization of symptoms through psychoeducation and skills - training, and some research has supported this advice. Offering such treatment as group therapy can be both cost - effective and give patients additional peer-support. The research project outlined in this proposal aims to investigate the effectiveness of stabilizing group treatment as an add-on to conventional treatment, for patients with PTSD or dissociative disorders after childhood abuse. This will be investigated in a randomized controlled design. The investigators also aim to discover psychophysiological markers associated with treatment, mechanisms of change involved in treatment, and what patient characteristics that predict outcome. The results may contribute to new knowledge about treatment of complex traumatization, as well as new and improved health services for a vulnerable patient group with little specialized treatment today.

The main aim of this project is to compare the effectiveness of stabilizing group treatment as an add-on to conventional individual therapy, to conventional individual therapy alone, in a randomized controlled design. This will be tested in two independent diagnostic groups: Patients with PTSD and patients with Dissociative disorders, both groups with reports of childhood abuse. The investigators will further investigate how level of dissociative symptoms influence treatment, how group climate influence symptoms, the relationship between individual and group therapy in combined treatment, and how treatment affects Heart Rate Variability. The investigators also seek to evaluate the treatment economically with a societal perspective, carrying out cost-utility analyses.
PURPOSE: To evaluate the predictive value of initial intraocular pressure difference of the detached and fellow eyes of patients with complex rhegmatogenous retinal detachment on postoperative persistent ocular hypotony.
METHODS: This retrospective observational study included 538 eyes of 538 unilateral complex rhegmatogenous retinal detachment patients with a proliferative vitreoretinopathy grade of C-1 or higher, treated with silicone oil endotamponade following pars plana vitrectomy. The patients were divided into Group A (patients having silicone oil removal without ocular hypotony; n=504) and Group B (patients with persistent ocular hypotony following silicone oil removal [n=8, 23.5%] and with retained silicone oil [n=26, 76.5%] due to the risk of persistent ocular hypotony; total n=34). Ocular hypotony was defined as an intraocular pressure of <6 mmHg on two or more occasions. Patients' demographics, including age, sex, and follow-up time, and ocular characteristics, including ocular surgical and trauma history, initial and final best-corrected visual acuity, intraocular pressure and initial intraocular pressure difference of the detached and fellow eyes, and anatomical success rates and postoperative complications, were retrospectively collected from the electronic patient files.
RESULTS: The initial intraocular pressure was significantly lower in the detached eyes of Group B than in Group A (8.3 ± 3.5 vs. 12.9 ± 3.3, p<0.001). Also, the initial intraocular pressure difference was significantly higher in Group B than in Group A (8.9 ± 3.2 vs. 2.2 ± 2.7mmHg, p<0.001). The receiver operating characteristic curve analysis showed that the cutoff value of the initial intraocular pressure difference was 7.5mmHg for the risk of persistent ocular hypotony. The most influential factors on postoperative persistent ocular hypotony in the binary logistic regression analysis were the initial intraocular pressure difference and the need for a retinectomy.
CONCLUSION: In eyes with complex rhegmatogenous retinal detachment treated with pars plana vitrectomy and silicone oil tamponade, the initial intraocular pressure difference could be of value in predicting postoperative persistent ocular hypotony and could guide surgeons on the decision of silicone oil removal.
In the manufacture of a medicament for treatment or prevention of chronic inflammatory conditions and clinical disorders associated with insulin resistance in an animal or human, soluble myeloid cell-surface glycoprotein (soluble CD14 (sCD14)) is used. ACTIVITY : Antiinflammatory; Antidiabetic; Anorectic; Antiarteriosclerotic; Hypotensive; Antilipemic. C57BL/6J ob/ob Male mice having obesity with hyperphagia, hyperinsulinemia, insulin resistance and moderate hyperglycemia were infused by recombinant myeloid cell-surface glycoprotein (rhCD14) (test) for 12 days by using Alzet (RTM; pump) implanted subcutaneously. Another group of mice (control) was administered with saline serum subcutaneously at a dosage of 1 Microg/g. After 16 hours of fasting, intraperitoneal glucose tolerance test (GTT) was carried out. Glucose (2 g/kg) was injected intraperitoneally. Blood samples (20 Microl) were taken from tail of mice at 0, 15, 30, 60, 120 and 180 minutes after glucose administration and blood glucose level was measured. It was observed that test treated mice showed decreased basal levels of serum glucose as compared to the control. The fasting blood glucose level for test/control was 153+-14/242+-30 mg/dL. The concentration of serum insulin also decreased concomitantly with the decrease in serum glucose in test treated mice. The results showed that the test had positive effect on normalization of blood glucose level and hence showed improved insulin sensitivity as compared to the control. MECHANISM OF ACTION : Lipopolysaccharide blocker.